A randomized placebo-controlled trial found that four months of treatment with dimethyl fumarate had a significant treatment effect on obstructive sleep apnea severity, reports Neurology Advisor.

“Dimethyl fumarate has anti-inflammatory effects, making it a useful therapy for certain inflammatory conditions,” lead study author and principal investigator Tiffany Braley, MD, MS, assistant professor of neurology at the University of Michigan, told Neurology Today. “Previous evidence has also suggested a role for inflammation in the pathogenesis of OSA, which is further supported by our findings. Although additional research is needed to understand the inflammatory processes underlying OSA, our study suggests that a medication believed to modulate systemic inflammation may partially improve apnea severity.”

Get the full story at lww.com